Skip to content
Open access

B-187: Agreement Rates Between an Alternate Cutoff for the Test of Memory Malingering and Other Performance Validity Tests

Oct 2026 · Archives of Clinical Neuropsychology · 0 citations

Abstract

Objective: Determine concordance rates for Test of Memory Malingering (TOMM) Trial 2 cutoff of ≤ 49 (established by Erdodi & Rai, 2017) and other performance validity tests (PVTs) from multiple cognitive domains. Method/Data Selection: Participants were 137 patients (60.6% female; 63.5% white) that underwent neuropsychological assessment between 2010 and 2026 in an outpatient university doctoral clinical psychology training and research clinic (M/SD: age = 33.2/13.1; education = 14.1/2.5). Participants were administered the TOMM, as well as seven other PVTs from multiple cognitive domains including: attention/processing speed, language, visuospatial, memory, and executive functions. A PVT for motor functioning was also included. Concordance rates were computed for each PVT and the TOMM. Results/Data Synthesis: Agreement rates for TOMM Trial 2 cutoff ≤ 49 and other PVTs ranged from 79.2% to 87.8%. Reliable Digit Span had the highest concordance rate (87.8%). The lowest concordance rates were for Boston Diagnostic Aphasia Examination Complex Ideation (79.2%) and Finger Tapping Test (79.4%). More conservative kappa coefficients for TOMM and other PVTs ranged from -.02 to .38, in the poor to fair range, most within the slight agreement range. Conclusions: Even the more stringent single error cutoff for TOMM Trial 2 has high agreement rates with other PVTs from multiple cognitive domains in a clinical sample. Although kappa coefficients often are reported in PVT studies, they likely underestimate the actual agreement rate of PVTs because guessing is not a factor in PVT classification and the high PVT pass rate typical of most clinical samples inflates the estimate of chance agreement.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.